Not medical advice. Talk to your provider before using any peptide.
Full disclaimerSemaglutide vs Tirzepatide
Peptide Schedule Research TeamReviewed Apr 202621 Citations
Side-by-side comparison of dosage, benefits, and side effects.
14.9% of body weight gone in 68 weeks. That number, from the STEP 1 trial (PMID 33567185, n=1,961), turned semaglutide into the most prescribed weight loss drug in modern medicine. Semaglutide (CAS 910463-68-2) is a GLP-1 receptor agonist sold as Ozempic, Wegovy, Wegovy HD, and Rybelsus. The drug mimics incretin hormone GLP-1. It binds receptors in the pancreas, the gut, and satiety centers in the hypothalamus. Pancreatic binding increases insulin secretion. Gut binding slows gastric emptying. Brain binding turns down hunger signals. An albumin-binding fatty acid side chain extends the half-life to roughly 7 days, allowing once-weekly dosing. Real-world use spans three FDA indications. Obesity patients follow the Wegovy titration from 0.25 mg up to 2.4 mg weekly (or 7.2 mg with the high-dose label approved March 2026). Type 2 diabetics typically land between 0.5 and 2.0 mg weekly on the Ozempic label. Cardiovascular patients stay at 2.4 mg long-term after SELECT (PMID 37952131) confirmed a 20% reduction in major adverse cardiovascular events across 17,604 participants. Community experience tracks the clinical data closely. Over 350,000 combined members across r/Ozempic and r/semaglutide consistently report appetite suppression, steady 1 to 2 lbs per week weight loss, and reduced food noise within the first month. The honest caveat: two-thirds of the weight returns within a year of stopping (STEP 1 extension data). Lean mass loss of 25 to 40% without resistance training is well-documented. This is a long-term commitment, not a quick fix. In SURMOUNT-5 (PMID 40353578, n=751), semaglutide 2.4 mg produced 13.7% weight loss versus 20.2% for tirzepatide 15 mg at 72 weeks. Semaglutide holds the stronger cardiovascular outcomes dataset: the SELECT trial (PMID 37952131, n=17,604) confirmed a 20% reduction in major adverse cardiovascular events over 39.8 months.
View full guide →20.2% body weight gone at 72 weeks, and that was the average, not the ceiling. Tirzepatide (LY3298176, CAS 2023788-19-2) is a 39-amino acid acylated lipopeptide sold as Zepbound for obesity and Mounjaro for type 2 diabetes. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. The dual receptor mechanism separates tirzepatide from single-target GLP-1 drugs like semaglutide. GIP receptor activation improves fat metabolism and may reduce the nausea burden that limits GLP-1-only treatment. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and boosts insulin secretion. Those two pathways working together produce weight loss and glycemic control that neither achieves alone. SURMOUNT-1 (PMID 35658024, n=2,539) showed dose-dependent results at 72 weeks: 15.0% weight loss at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg. SURMOUNT-5 (PMID 40353578, n=751) ran a direct comparison; tirzepatide reached 20.2% versus semaglutide's 13.7%. Roughly one in five tirzepatide patients lost 30% or more of their body weight. The r/Zepbound community (180,000+ members) confirms what the trials found. Appetite suppression starts within days. Most users stabilize at 7.5 to 12.5 mg rather than pushing to the maximum 15 mg dose. Cost and insurance coverage remain the biggest barriers. Weight regain after stopping is well-documented; about two-thirds of lost weight returns within a year of discontinuation.
View full guide →At a Glance
| Attribute |  Semaglutide |  Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Safety Grade | A | A |
| Half-Life | ~7 days | ~5 days |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 5mg, 10mg | 5mg, 10mg, 15mg |
| Beginner Dose | 250mcg Weekly | 2500mcg Weekly |
| Moderate Dose | 500mcg Weekly | 5000mcg Weekly |
| Aggressive Dose | 1000mcg Weekly | 10000mcg Weekly |
| Dosing Source | FDA Label | FDA Label |
| Side Effects | Black box warning: semaglutide causes thyroid C-cell tumors in rodents. Whether it causes medullary thyroid carcinoma in humans is unknown. Anyone with a personal or family history of MTC or MEN2 cannot use this drug. That warning is printed on every Wegovy and Ozempic label, and it stays there. GI side effects dominate the titration period. Nausea hits 40 to 50% of patients during the first weeks at each new dose level. For some, that nausea is severe enough to impact daily function and work productivity. Community consensus recommends extending each titration step to 6 to 8 weeks rather than 4 if nausea is bad. The nausea typically fades within the first week at each stable dose. Constipation affects the majority of long-term users. Proactive fiber supplementation (psyllium husk from day one) is the top community recommendation. Magnesium citrate at 200 to 400 mg before bed serves as the standard backup. Vomiting and diarrhea also occur, usually transiently during dose escalation. Rare but serious: pancreatitis requires immediate emergency evaluation if you experience severe abdominal pain radiating to the back. Gallbladder disease (cholelithiasis, cholecystitis) is a known complication, particularly with rapid weight loss. Acute kidney injury can result from dehydration driven by persistent GI symptoms. FDA postmarketing warnings from September 2023 flagged three additional signals. Ileus (intestinal obstruction) requires emergency care if you develop severe persistent abdominal pain. Diabetic retinopathy complications can paradoxically worsen with rapid A1c improvement in patients with pre-existing retinopathy. Resting heart rate increases a mean 1 to 4 bpm; 26% of SELECT participants had increases of 20 bpm or more. The 7.2 mg Wegovy HD dose introduced a new signal: dysesthesia (tingling, numbness) in 18.9% of patients vs. 0% on placebo in STEP UP. That adverse event profile is still being characterized. Hair thinning from telogen effluvium peaks between months 3 and 6. It is a response to rapid weight loss, not a direct drug effect. It typically resolves by month 8 to 12 with adequate protein intake. Lean mass loss of 25 to 40% of total weight lost is documented without resistance training. "Ozempic face" (facial volume loss) becomes visible after 30+ lbs of weight loss. Contraindications: personal or family history of MTC or MEN2, history of pancreatitis, pregnancy or breastfeeding, hypersensitivity to semaglutide, severe gastrointestinal disease including gastroparesis. If you are on insulin or sulfonylureas, doses of those drugs typically need a 20 to 30% reduction at semaglutide initiation to prevent hypoglycemia. | Tirzepatide carries a black box warning for thyroid C-cell tumors. In rodent studies, it caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this translates to humans is unknown, and no confirmed human cases have been attributed to tirzepatide. The drug is contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Gastrointestinal side effects are the most common reason people struggle with tirzepatide. In the SURMOUNT and SURPASS trials, nausea affected 17 to 25% of patients (dose-dependent, worst during dose escalation). Diarrhea occurred in 13 to 17%. Vomiting hit 8 to 10%. Constipation affected 7 to 11%. Most of these effects are mild-to-moderate and improve with slow dose titration; the community-preferred 6 to 8 week steps between dose increases reduce GI burden compared to the FDA label's 4-week minimum. Decreased appetite (9 to 11%) is technically a side effect, though most users consider it the primary benefit. Sulfur burps are a community-reported nuisance during escalation phases that clinical trials don't track well. Hair thinning (telogen effluvium) affects roughly 4 to 5% of users versus about 1% on placebo. This isn't a direct drug effect. Rapid weight loss and caloric restriction trigger a hair growth cycle shift that typically starts 2 to 3 months in and resolves on its own by month 9 to 12. Injection-site reactions occur in 4 to 7% of patients. Rotating injection sites between the abdomen, thigh, and upper arm helps. Let the vial reach room temperature for 15 to 20 minutes before injecting. Pancreatitis is rare but serious. Severe, persistent abdominal pain warrants immediate medical evaluation. Serum lipase testing should happen only when pancreatitis is clinically suspected; routine screening isn't indicated. Gallbladder disease and hypersensitivity reactions are uncommon but documented in clinical trials. Stop tirzepatide and seek medical care if you develop signs of anaphylaxis, severe abdominal pain, or jaundice. Muscle loss is a legitimate concern. Approximately 25% of weight lost on tirzepatide is lean mass (SURMOUNT-1 body composition data). Resistance training 3 to 4 times per week and protein intake of at least 1.2 g/kg body weight per day are the primary countermeasures. Pregnancy and breastfeeding: tirzepatide is contraindicated. Stop treatment at least 2 months before planned conception due to the 5-day half-life and limited reproductive safety data. |
Key Differences
- Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 agonist, which is what drives its larger average weight loss.
- Tirzepatide pulled ahead head-to-head. SURMOUNT-1 landed on 22.5% mean weight loss at 72 weeks versus 14.9% for semaglutide in STEP 1.
- Both need slow titration, but tirzepatide starts at higher doses (2.5mg vs 0.25mg), so expect more intense GI side effects during the first month.
- Semaglutide has the longer market history and the larger cardiovascular outcomes dataset (SELECT, n=17,604, 20% MACE reduction).
When to Choose Semaglutide
- Longer real-world safety track record matters (FDA-approved since 2017, SELECT cardiovascular data)
- Moderate, sustainable weight loss is the goal (14.9% at 68 weeks in STEP 1)
- Cost is a deciding factor (compounded and brand options often run cheaper than tirzepatide)
- You've responded well to single GLP-1 therapy and don't need a second mechanism
When to Choose Tirzepatide
- Maximum weight loss is the priority (SURMOUNT-1 landed on 22.5% at 72 weeks)
- Single GLP-1 therapy hasn't produced adequate results
- Blood sugar control and insulin sensitivity are secondary goals
- You want the dual GIP/GLP-1 mechanism for a larger average response
Can You Stack Semaglutide + Tirzepatide?
Semaglutide and tirzepatide shouldn't be stacked. Tirzepatide already covers the GLP-1 pathway, so adding semaglutide would double stimulation at the same receptor. The result is severe GI side effects with no extra benefit. Pick one based on your weight loss goal, your response history, and your insurance coverage.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.